Results from a recent AC Nielsen survey show increasing demand for all types of silicone hydrogel contact lenses, stimulated by continuing new product introductions.

As of February 2005, U.S. retail sales of silicone hydrogels increased by 161% vs. the previous year, boosting total soft contact lens sales 12%. Silicone hydrogels now make up 19% of soft lens retail sales, compared to 8% in January/February 2004.

The FDA approved the first intravitreal drug implant, Retisert (fluocinolone acetonide, Bausch & Lomb) for the treatment of chronic non-infectious uveitis of the posterior segment. Bausch & Lomb describes the implant as a tiny drug reservoir designed to deliver a sustained level of corticosteroid directly to the back of the eye for about two-and-a-half years (30 months).

Alcon got the OK from the FDA for its AcrySof ReStor intraocular lens for cataract patients with and without presbyopia. Alcon says the lens uses apodized diffractive technology to give patients a full range of vision. After insertion of the IOL, 80% of patients who participated in a clinical study did not use glasses for any activities.